1301 Harbor Bay Parkway
425 articles with BioTime, Inc.
BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen
BioTime, Inc. announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY.
BioTime, Inc., a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, 2018.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA.
BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem
Distribution to Commence Today at 5:00pm ET
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Industry Veteran Brian M. Culley Appointed as CEO
BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology
Shares of Asterias Biotherapeutics have soared nearly 30 percent in premarket trading after it was announced that the Fremont, Calif.-based company was being absorbed by BioTime, Inc. in an attempt to create a leading cell therapy company.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and operating results.
Sale of AgeX subsidiary will help support development of BioTime’s core programs
BioTime, Inc. today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8th, 2018.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®
BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
BioTime Shareholders To Receive One Share of AgeX Common Stock for Every 10 Shares of BioTime Common Stock
BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee
BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
BioTime, Inc. today announced that Francois Binette, Senior Vice President and BioTime’s Head of Global Development, will participate in a panel discussion at the National Eye Institute Conference at 10:15am ET/7:15am PT on Tuesday, September 25, 2018 in Bethesda, Maryland.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
BioTime, Inc. is advising the holders of its publicly traded warrants (NYSE American: BTX.WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 1, 2018 (the “Expiration Date”).
Former Co-CEO Adi Mohanty to Aid in Transition and Continue to Serve on the Boards of Asterias and OncoCyte